However, the combination of both antibodies induced a significant additive increase in the cytotoxic capacity of PBMCs when confronted with the MDA-MB-231 tumor cells (Figure 6C), providing the first evidence for the successful use of itolizumab in combination with other ICI in the treatment of CD318+ solid tumors. This evidence concerns the gene CDCP1 and neoplasm.